PMC:7556165 / 4161-4378
Annnotations
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T26 | 129-139 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
| T27 | 129-133 | Species | denotes | SARS | NCBItxid:694009 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T30 | 34-213 | Sentence | denotes | On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research. |
LitCovid-sample-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T7 | 47-51 | Body_part | denotes | hand | http://purl.obolibrary.org/obo/UBERON_0002398 |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 145 | 87-91 | Gene | denotes | ACE2 | Gene:59272 |
| 146 | 107-111 | Gene | denotes | ACE2 | Gene:59272 |
| 147 | 129-139 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T531 | 87-91 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
| T532 | 107-111 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T17 | 3-9 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | object |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T18 | 47-51 | Body_part | denotes | hand | http://purl.org/sig/ont/fma/fma9712 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T35 | 129-139 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T36 | 129-133 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-PD-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T7 | 47-51 | http://purl.obolibrary.org/obo/MAT_0000091 | denotes | hand |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 145 | 87-91 | Gene | denotes | ACE2 | Gene:59272 |
| 146 | 107-111 | Gene | denotes | ACE2 | Gene:59272 |
| 147 | 129-139 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T30 | 34-213 | Sentence | denotes | On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research. |